Logo image of ERYP

ERYTECH PHARMA - SPON ADR (ERYP) Stock Fundamental Analysis

NASDAQ:ERYP - Nasdaq - US29604W1080 - ADR - Currency: USD

0.78  0 (0%)

Fundamental Rating

2

ERYP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of ERYP have multiple concerns. ERYP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ERYP has reported negative net income.
In the past year ERYP has reported a negative cash flow from operations.
In the past 5 years ERYP always reported negative net income.
ERYP had a negative operating cash flow in each of the past 5 years.
ERYP Yearly Net Income VS EBIT VS OCF VS FCFERYP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The profitability ratios for ERYP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ERYP Yearly ROA, ROE, ROICERYP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

ERYP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERYP Yearly Profit, Operating, Gross MarginsERYP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ERYP has about the same amount of shares outstanding.
The debt/assets ratio for ERYP has been reduced compared to a year ago.
ERYP Yearly Shares OutstandingERYP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
ERYP Yearly Total Debt VS Total AssetsERYP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.54, we must say that ERYP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.54, ERYP perfoms like the industry average, outperforming 45.57% of the companies in the same industry.
ERYP has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.44, ERYP is doing worse than 71.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -2.54
ROIC/WACCN/A
WACC4.93%
ERYP Yearly LT Debt VS Equity VS FCFERYP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

ERYP has a Current Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
ERYP's Current ratio of 3.65 is on the low side compared to the rest of the industry. ERYP is outperformed by 61.67% of its industry peers.
A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.65, ERYP is doing worse than 60.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
ERYP Yearly Current Assets VS Current LiabilitesERYP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

ERYP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
ERYP shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.04%.
ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%

3.2 Future

The Earnings Per Share is expected to grow by 26.28% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -44.77% on average over the next years. This is quite bad
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ERYP Yearly Revenue VS EstimatesERYP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
ERYP Yearly EPS VS EstimatesERYP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERYP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERYP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERYP Price Earnings VS Forward Price EarningsERYP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERYP Per share dataERYP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

ERYP's earnings are expected to grow with 26.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ERYP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERYTECH PHARMA - SPON ADR

NASDAQ:ERYP (6/28/2023, 8:00:02 PM)

0.78

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2023-05-09/amc
Earnings (Next)09-11 2023-09-11/amc
Inst Owners0.04%
Inst Owner Change-91.11%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap26.61M
Analysts42.22
Price Target3.94 (405.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)307.94%
Min Revenue beat(2)-81.61%
Max Revenue beat(2)697.48%
Revenue beat(4)1
Avg Revenue beat(4)118.61%
Min Revenue beat(4)-81.61%
Max Revenue beat(4)697.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.19
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.24
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -2.54
F-Score4
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)458.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A